Celgene reports positive pancreatic cancer data for Abraxane

Celgene has reported positive data from a new trial that shows the benefits of a combination pancreatic cancer treatment regimen involving its drug Abraxane.

Results from the phase III study showed that Abraxane – when used in combination with gemcitabine in treatment-naive patients – delivered overall survival benefits for sufferers of advanced pancreatic cancer.

The combination regimen delivered a better performance than gemcitabine alone, meaning it was able to meet its primary efficacy endpoint in the trial.

Based on the results of this study, Celgene plans to submit the drug for approval in this indication to healthcare regulators in the US, Europe and other markets.

Abraxane has been commercially available since 2005 and is currently approved for use among breast and lung cancer patients.

Last month, the company reported its financial results for the third quarter of 2012, during which it experienced a 14 percent year-over-year increase in revenues thanks in part to rising demand for Abraxane.